Get the Stockscreener App
17.91
3.97%
-0.74
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Great Point Partners LLC Makes New Investment in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.33 - MarketBeat
Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Cartesian therapeutics CTO sells $649,029 in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics CTO sells $649,029 in stock - Investing.com India
Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire
Cartesian Therapeutics to Present Key Phase 2b Trial Data for Myasthenia Gravis Treatment | RNAC Stock News - StockTitan
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million By Investing.com - Investing.com Nigeria
Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com
Cartesian Therapeutics executive sells $875,042 in stock - Investing.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance
Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN
HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat
Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan
Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - GlobeNewswire
Cartesian's Novel mRNA CAR-T Therapy Data Selected for Major ASH Conference Spotlight | RNAC Stock News - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance
Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan
Insider Buying Slows, but Not for These 7 Buyers - 24/7 Wall St.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat
30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN
Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa
Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):